Expert Opinion on Investigational Drugs

Papers
(The H4-Index of Expert Opinion on Investigational Drugs is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?74
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer74
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond70
Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases68
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials67
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)66
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives60
Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors51
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?51
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects50
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success44
Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases44
The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment41
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer40
Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies39
Risuteganib—a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema38
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)38
Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis38
Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas38
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis36
Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease36
Novel emerging therapies in atherosclerosis targeting lipid metabolism36
Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis36
Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis36
ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease36
The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer34
Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma32
Anti-integrin therapy for retinovascular diseases32
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential32
BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure31
New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis31
Givinostat: an emerging treatment for polycythemia vera31
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis31
0.025589942932129